Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Altimmune (ALT) Total Debt (2016 - 2025)

Altimmune (ALT) has disclosed Total Debt for 13 consecutive years, with $34.3 million as the latest value for Q4 2025.

  • Quarterly Total Debt changed N/A to $34.3 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $34.3 million through Dec 2025, changed N/A year-over-year, with the annual reading at $34.3 million for FY2025, N/A changed from the prior year.
  • Total Debt for Q4 2025 was $34.3 million at Altimmune, up from $14.4 million in the prior quarter.
  • The five-year high for Total Debt was $34.3 million in Q4 2025, with the low at $1.5 million in Q2 2022.
  • Average Total Debt over 4 years is $7.5 million, with a median of $4.5 million recorded in 2022.
  • The sharpest move saw Total Debt surged 312.59% in 2021, then tumbled 39.28% in 2022.
  • Over 4 years, Total Debt stood at $7.5 million in 2021, then crashed by 39.28% to $4.6 million in 2022, then fell by 6.02% to $4.3 million in 2023, then skyrocketed by 696.45% to $34.3 million in 2025.
  • According to Business Quant data, Total Debt over the past three periods came in at $34.3 million, $14.4 million, and $14.3 million for Q4 2025, Q3 2025, and Q2 2025 respectively.